静脉血栓栓塞症治疗市场规模、份额及成长分析（按产品、适应症、最终用户和地区）－2025-2032 年产业预测

2023 年全球静脉血栓栓塞症治疗市场规模价值 22 亿美元，预计将从 2024 年的 23.1 亿美元增长到 2032 年的 34.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.0%。

静脉血栓栓塞症(VTE) 治疗市场在解决全球重大健康问题方面发挥关键作用，该问题的特征是静脉血栓形成，可导致肺动脉栓塞和深层静脉栓塞症等严重併发症。该市场的主要驱动因素包括久坐的生活方式、人口老化以及手术相关静脉血栓栓塞症 (VTE) 盛行率上升，从而产生了对有效治疗的需求。抗凝血治疗的进步，特别是直接口服抗凝血剂 (DOAC) 和注射剂，在最大限度地降低出血风险的同时改善了治疗效果。人们对风险因素和早期诊断重要性的认识不断提高，进一步推动了市场的成长。儘管存在个人化治疗方法和患者依从性等挑战，VTE 治疗市场在提供挽救生命的干预措施方面仍然至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

静脉血栓栓塞症治疗市场规模（依产品及复合年增长率）（2025-2032）

• 市场概览
• 非分段式空气压缩泵
• 无梯度分段式空气压缩泵
• 带有校准梯度的分段式空气压缩泵
• 上部空气压缩套
• 下部空气压缩套
• 永久性下腔静脉滤器
• 可回收下腔静脉滤器
• 栓塞移除球囊导管
• 经皮血栓切除装置
• 导管直接溶栓（CDT）装置

静脉血栓栓塞症治疗市场规模（依适应症及复合年增长率）（2025-2032）

• 市场概览
• 深层静脉栓塞症
• 肺动脉栓塞

静脉血栓栓塞症治疗市场规模（按最终用户和复合年增长率划分）（2025-2032）

• 市场概览
• 医院
• 导管室
• 门诊手术中心

静脉血栓栓塞症治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Bayer AG（Germany）
• Bristol Myers Squibb（USA）
• Daiichi Sankyo Company, Limited（Japan）
• Boehringer Ingelheim（Germany）
• Novartis AG（Switzerland）
• Aspen Pharmacare Holdings Limited（South Africa）
• Abbott Laboratories（USA）
• Medtronic plc（Ireland）
• Boston Scientific Corporation（USA）
• Cardinal Health, Inc.（USA）
• Terumo Corporation（Japan）
• Cook Medical（USA）
• Getinge AB（Sweden）
• Teleflex Incorporated（USA）
• Smith+Nephew（UK）
• Baxter International Inc.（USA）
• Instrumentation Laboratory（USA）

结论和建议

Global Venous Thromboembolism Treatment Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.31 billion in 2024 to USD 3.41 billion by 2032, growing at a CAGR of 5.0% during the forecast period (2025-2032).

The venous thromboembolism (VTE) treatment market plays a crucial role in addressing a significant global health issue marked by blood clot formation in veins, which can lead to serious complications such as pulmonary embolism and deep vein thrombosis. Key drivers of this market include the rising prevalence of VTE linked to sedentary lifestyles, aging populations, and surgical procedures, creating a demand for effective treatments. Advancements in anticoagulant therapies, particularly direct oral anticoagulants (DOACs) and injectable options, have improved treatment outcomes while minimizing bleeding risks. Increased awareness of risk factors and the importance of early diagnosis further bolster market growth. Despite challenges like the need for personalized treatment approaches and patient compliance, the VTE treatment market remains vital in delivering life-saving interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Venous Thromboembolism Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Venous Thromboembolism Treatment Market Segments Analysis

Global Venous Thromboembolism Treatment Market is segmented by Product, Disease Indication, End User and region. Based on Product, the market is segmented into Non-Segmented Pneumatic Compression Pumps, Segmented Pneumatic Compression Pumps without Gradient, Segmented Pneumatic Compression Pumps with Calibrated Gradient, Upper Pneumatic Compression Sleeves, Lower Pneumatic Compression Sleeves, Permanent Inferior Vena Cava Filters, Retrievable Inferior Vena Cava Filters, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices and Catheter-Directed Thrombolysis (CDT) Devices. Based on Disease Indication, the market is segmented into Deep Venous Thrombosis and Pulmonary Embolism. Based on End User, the market is segmented into Hospitals, Catheterisation Laboratories and Ambulatory Surgical Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Venous Thromboembolism Treatment Market

The global market for Venous Thromboembolism (VTE) treatment is significantly influenced by the rising prevalence of VTE cases, which is attributed to several factors including aging populations, sedentary lifestyles, and post-surgical complications. As VTE presents serious health challenges, there is an increasing emphasis on its timely detection and effective treatment. This heightened awareness and focus on managing VTE are propelling the growth of the market, as healthcare providers and patients alike prioritize strategies to mitigate the risks associated with this condition. Consequently, investment in innovative treatment options and preventive measures is becoming increasingly vital in addressing this public health concern.

Restraints in the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism (VTE) Treatment market faces a significant restraint due to the complexity and length of treatment regimens required to effectively manage VTE. These intricate protocols can lead to challenges in patient adherence, as the extended duration and demanding nature of the treatments may overwhelm individuals. Consequently, non-compliance can adversely affect the overall outcomes of the treatment, hindering progress and recovery. This issue emphasizes the need for strategies to simplify treatment plans and enhance patient engagement in order to improve therapeutic results and ensure a more effective management of VTE across diverse populations.

Market Trends of the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism (VTE) Treatment market is witnessing a significant trend towards the adoption of Direct Oral Anticoagulants (DOACs), which have gained popularity for their superior efficacy and convenience compared to traditional warfarin. Medications such as apixaban, rivaroxaban, and edoxaban are favored due to their reduced monitoring requirements and ease of use, making them increasingly attractive to both healthcare providers and patients. This paradigm shift is expected to drive market growth, as healthcare systems increasingly recognize the benefits of DOACs, ultimately improving patient outcomes and adherence in VTE management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Venous Thromboembolism Treatment Market Size by Product & CAGR (2025-2032)

• Market Overview
• Non-Segmented Pneumatic Compression Pumps
• Segmented Pneumatic Compression Pumps without Gradient
• Segmented Pneumatic Compression Pumps with Calibrated Gradient
• Upper Pneumatic Compression Sleeves
• Lower Pneumatic Compression Sleeves
• Permanent Inferior Vena Cava Filters
• Retrievable Inferior Vena Cava Filters
• Embolectomy Balloon Catheters
• Percutaneous Thrombectomy Devices
• Catheter-Directed Thrombolysis (CDT) Devices

Global Venous Thromboembolism Treatment Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Deep Venous Thrombosis
• Pulmonary Embolism

Global Venous Thromboembolism Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Catheterisation Laboratories
• Ambulatory Surgical Centres

Global Venous Thromboembolism Treatment Market Size & CAGR (2025-2032)

• North America (Product, Disease Indication, End User)
  • US
  • Canada
• Europe (Product, Disease Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Disease Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Disease Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Disease Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare Holdings Limited (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith+Nephew (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instrumentation Laboratory (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations